The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 March 2026•

1 min read

BridgeBio Pharma to Present Long-Term Acoramidis Data at ACC Scientific Sessions

Key Facts

1BridgeBio Pharma will present long-term efficacy and safety data for acoramidis from the ATTRibute-CM OLE trial.

2The data will be shared in a late-breaking oral presentation at the ACC Annual Scientific Sessions on March 28-30, 2026.

Version History

2 additional sources confirmed this story

BridgeBio Pharma has announced it will present long-term efficacy and safety data for its drug, acoramidis, at the upcoming American College of Cardiology (ACC) Annual Scientific Sessions. The data, derived from the Phase 3 ATTRibute-CM open-label extension (OLE) trial, will be featured in a late-breaking oral presentation. This presentation is scheduled to take place between March 28 and March 30, 2026, highlighting the drug's performance in treating transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis remains a critical asset in BridgeBio's clinical pipeline, and these long-term results are essential for its market positioning. Industry experts view late-breaking presentations at major medical conferences as significant catalysts for biotechnology stocks. Positive outcomes could potentially enhance the drug's competitive profile against existing treatments for ATTR-CM.